Accutane
In brief
- Accutane (isotretinoin) is a prescription-only medicine (POM) in the UK and should be obtained from a pharmacy with a valid prescription and appropriate pregnancy-prevention measures.
- Accutane is used for severe nodular or cystic acne and is a systemic retinoid (13-cis-retinoic acid) that reduces sebaceous gland size and sebum production, normalises follicular keratinisation and has anti-inflammatory effects.
- Usual dosing starts at about 0.5 mg/kg/day (divided once or twice daily), titrated up to 1 mg/kg/day as tolerated, with a cumulative target dose of roughly 120–150 mg/kg over the course of treatment; take with food for optimal absorption.
- The form of administration is oral soft-gelatin capsules, commonly in 10 mg, 20 mg, 30 mg and 40 mg strengths (packs of 10–60 capsules).
- Improvement often begins within 2–6 weeks, with more noticeable benefit by 4–8 weeks; an initial temporary worsening of acne can occur in the first weeks.
- Treatment courses typically run 16–24 weeks to reach the cumulative dose; many patients experience prolonged remission after a single course, though relapse may occur and repeat courses are sometimes needed after an interval.
- Avoid or limit alcohol while taking Accutane because combined alcohol and isotretinoin use increases the risk of elevated liver enzymes and raised triglycerides and may worsen hepatotoxicity.
- The most common side effect is cheilitis (dry, inflamed lips); other frequent effects include dry skin and mucous membranes, nosebleeds, musculoskeletal aches, temporary acne flare, photosensitivity, and elevated liver enzymes and blood lipids.
- Would you like to try Accutane without a prescription?
Basic Accutane information
- INN (international nonproprietary name): Isotretinoin (also referred to as 13‑cis‑retinoic acid).
- Brand names available in the United Kingdom: Roaccutane and generic isotretinoin capsules.
- ATC code: D10BA01.
- Forms and dosages: Soft gelatin capsules commonly 10 mg and 20 mg; sometimes available as 5 mg, 30 mg or 40 mg strengths; typical pack sizes 10, 30 or 60 capsules.
- Registration status in the United Kingdom: Prescription-only medicine (POM); supply is subject to a pregnancy prevention programme.
- OTC / Rx classification: Prescription‑only (Rx) due to teratogenic risk and adverse effect profile.
Critical warnings and restrictions (safety first)
High‑risk groups (pregnancy, elderly, chronic illness)
Isotretinoin is highly teratogenic and must never be used during pregnancy or breastfeeding.
Pregnancy prevention programmes are mandatory in UK practice and must be enforced by prescribers and pharmacists.
Absolute contraindications include pregnancy, breastfeeding, severe hepatic insufficiency, hypervitaminosis A and known allergy to isotretinoin or excipients such as soya or peanut traces.
Use extreme caution with a history of depression or severe psychiatric illness, diabetes, dyslipidaemia or chronic alcoholism.
Start elderly patients at lower doses and monitor more closely because tolerability and comorbidity burden increase with age.
- Contraindications: Pregnancy; Breastfeeding; Severe hepatic insufficiency; Hypervitaminosis A; Allergy to isotretinoin or excipients.
- Relative risk conditions: History of depression or psychiatric illness; Diabetes mellitus; Dyslipidaemia; Chronic alcoholism; Severe obesity.
- Monitoring schedule: Baseline pregnancy test when applicable; baseline LFTs and fasting lipids; repeat LFTs and lipids at 4–8 weeks then periodically; mood checks at baseline and during treatment.
Checklist — pregnancy prevention steps
- Confirm negative pregnancy test before starting treatment.
- Use reliable contraception starting at least one month before therapy if applicable, and throughout treatment.
- Repeat pregnancy tests monthly during therapy as per prescriber protocol.
- Continue contraception for a prescriber‑specified period after stopping (follow prescriber protocol).
- Provide clear verbal and written counselling about teratogenic risk and emergency contact details.
| High‑risk group | Action required |
|---|---|
| Women of childbearing potential | Negative pregnancy test before start; two reliable forms of contraception as per prescriber; monthly tests where required. |
| Pregnant or breastfeeding women | Absolute contraindication; immediate cessation and urgent obstetric review if exposure suspected. |
| Patients with liver disease | Avoid in severe hepatic insufficiency; lower dose or avoid in mild/moderate impairment; monitor LFTs frequently. |
| History of psychiatric illness | Assess baseline mental health; monitor closely and refer to mental health services for concerning symptoms. |
| Elderly patients | Start low and monitor for adverse effects and interactions due to polypharmacy. |
Interaction with activities (driving, workplace safety under UK law)
Isotretinoin can cause dizziness, visual disturbances and fatigue in some patients.
Advise patients not to drive or operate heavy machinery if they experience these symptoms.
For safety‑critical occupations, document fitness to work and liaise with occupational health and the employer following HSE and employer policies.
Q&A — “Can I drive after taking it in the UK?”
Short answer: Usually yes, but only if you feel well.
If you experience dizziness, blurred vision, severe fatigue or mood changes, do not drive and contact your GP or pharmacist.
Record advice in workplace occupational health records if the role is safety critical.
Usage basics
INN, brand names available in the UK
The INN is isotretinoin, also called 13‑cis‑retinoic acid and classified under ATC D10BA01.
In UK practice you will most commonly see generic isotretinoin and Roaccutane referenced in prescribing and patient materials.
Formulation is oral soft gelatin capsules, typically 10 mg and 20 mg strengths, sometimes 30–40 mg strengths.
Legal classification (POM, P, GSL)
Isotretinoin is a Prescription‑Only Medicine (POM) across the UK and must only be dispensed on a valid prescription.
Dispensing follows MHRA and NHS prescribing protocols with enhanced safety checks such as pregnancy testing and documented counselling.
Pharmacies dispense isotretinoin only on valid prescriptions.
| Brand / formulation | Strengths | Notes |
|---|---|---|
| Roaccutane | 10 mg, 20 mg, 30 mg | Historically marketed; generics available. |
| Generic isotretinoin capsules | 10 mg, 20 mg, 30 mg, 40 mg | Multiple manufacturers. |
- Packaging features: blister or strip packs with safety warnings and patient information leaflets.
- Patient leaflets include pregnancy warnings and monitoring requirements.
- INN
- Isotretinoin.
- ATC
- D10BA01.
- POM
- Prescription‑Only Medicine.
Dosing guide
Standard regimens (NHS guidelines)
Typical starting dose is weight‑based at about 0.5 mg/kg/day in one or two divided doses.
Dose can be titrated up to approximately 1 mg/kg/day as tolerated.
The common cumulative target is 120–150 mg/kg usually reached over a 16–24 week course.
Take isotretinoin with food to maximise absorption.
Baseline and on‑treatment monitoring should include liver function tests, fasting lipids and pregnancy tests where relevant, together with mood assessment.
Adjust dose for intolerance rather than omit or skip monitoring.
Adjustments for comorbidities
- Liver impairment: contraindicated in severe hepatic insufficiency; use caution and lower dose in mild/moderate dysfunction with frequent LFT monitoring.
- Renal impairment: use cautiously with lower starting doses and slow titration.
- Dyslipidaemia: monitor lipids and liaise with the GP or lipid clinic if levels rise.
- Elderly: start at the lower end of dosing and monitor for adverse effects and interactions.
Q&A — “What if I miss a dose?”
If you remember the same day, take the missed dose with food.
Do not double the next dose to compensate.
If more than 24 hours have passed, skip the missed dose and continue the usual schedule.
Report frequent missed doses to the prescriber because efficacy is linked to cumulative dose.
| Weight | Approx. Starting Dose (0.5 mg/kg) | Approx. Target daily dose (1 mg/kg) |
|---|---|---|
| 50 kg | 25 mg/day | 50 mg/day |
| 70 kg | 35 mg/day | 70 mg/day |
| 90 kg | 45 mg/day | 90 mg/day |
Checklist — baseline tests
- Pregnancy test for women of childbearing potential.
- Full liver function tests.
- Fasting lipid profile.
- Baseline mental health screen and medication review.
Interaction chart
Food and drinks (alcohol, tea/coffee, diet habits)
Isotretinoin absorption improves with a fatty meal, so advise taking capsules with food.
Alcohol can increase the risk of liver injury and hypertriglyceridaemia and should be avoided or minimised while on treatment.
No direct interaction is reported with tea or coffee, but keeping a consistent food routine helps adherence.
Common drug conflicts
Avoid concurrent systemic vitamin A supplements because of hypervitaminosis A risk.
Do not co‑prescribe oral tetracyclines such as doxycycline or minocycline due to risk of intracranial hypertension.
Review concomitant psychotropic medicines and lithium and monitor closely if combined.
Report suspected adverse reactions via the MHRA Yellow Card scheme as recommended.
| Drug / food | Interaction | Clinical action |
|---|---|---|
| Vitamin A supplements | Increased risk of hypervitaminosis A | Stop supplements before starting isotretinoin. |
| Oral tetracyclines | Raised risk of intracranial hypertension | Avoid concurrent use; choose alternative antibiotic if needed. |
| Alcohol | Higher risk of liver toxicity and hypertriglyceridaemia | Advise minimisation or abstinence; monitor LFTs and lipids. |
| Lithium / psychotropics | Possible increased psychiatric risks or pharmacodynamic interactions | Review with prescriber; close monitoring. |
- High‑risk combinations include isotretinoin plus systemic vitamin A or tetracyclines.
- Advise stopping non‑essential supplements containing vitamin A prior to initiation.
Legal status and availability in the UK
In the UK isotretinoin is dispensed only on prescription from GPs, dermatology clinics or private prescribers.
In our online pharmacy, Accutane is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.
Mechanism and pharmacology
Simplified explanation
Isotretinoin is a systemic retinoid that reduces sebaceous gland size and sebum production.
It normalises follicular keratinisation and has anti‑inflammatory effects which together reduce nodules and cysts.
These mechanisms explain the high efficacy seen in severe nodular or cystic acne compared with conservatively managed cases.
Clinical terms
- Pharmacokinetics
- Oral soft gelatin capsules with better absorption when taken with a fatty meal.
- Side‑effect mechanism
- Mucocutaneous side effects arise from retinoid effects on epithelial and mucous membranes, while liver and lipid effects reflect systemic metabolism.
- Cumulative dose effect
- Higher cumulative dosing correlates with reduced relapse rates.
| Mechanism | Clinical effect |
|---|---|
| Reduced sebum production | Fewer comedones and inflammatory lesions |
| Normalised keratinisation | Less follicular plugging and cyst formation |
| Anti‑inflammatory action | Reduced red swollen nodules |
- Key pharmacokinetic point: take with food for optimal absorption.
- Side effects are predictable and reversible in most cases on dose adjustment or cessation.
Indications and off‑label uses
MHRA‑approved uses
The primary indication is severe recalcitrant nodular or cystic acne unresponsive to conventional therapy.
Prescription‑only status and pregnancy prevention measures are mandated by the MHRA.
Off‑label practices in NHS and private care
Occasional off‑label use occurs for severe rosacea variants or other follicular disorders but only under dermatology supervision.
Private clinics may vary thresholds for initiation, but every off‑label use requires clear informed consent and documentation.
Alternatives should be considered first and the rationale recorded when isotretinoin is chosen off‑label.
| Indication | Evidence strength |
|---|---|
| Severe nodular/cystic acne | High |
| Severe refractory rosacea (specialist use) | Limited / specialist opinion |
- Off‑label indications should be managed by dermatology teams with documented consent.
- Checklist for consent: explanation of teratogenic risk, monitoring plan, alternatives, expected timeline and side effects.
Alternatives matrix
NHS prescribing alternatives (comparison table)
| Drug class | Examples | Typical efficacy | Monitoring | Contraindications |
|---|---|---|---|---|
| Topical retinoids | Tretinoin, Adapalene | Good for mild–moderate acne | Minimal | Local irritation; not suitable for severe nodular disease |
| Oral antibiotics | Doxycycline, Minocycline | Moderate for inflammatory acne | Baseline bloods sometimes; monitor for side effects | Tetracycline contraindications; avoid with isotretinoin |
| Hormonal agents | Combined oral contraceptives, Spironolactone | Effective in appropriate women | Blood pressure and potassium monitoring for spironolactone | Pregnancy risk considerations; not for men |
Pros and cons checklist
- Isotretinoin: Very effective but needs stringent monitoring and is teratogenic.
- Antibiotics: Easier monitoring but risk of resistance with long courses.
- Hormonal therapies: Good option for many women but require contraceptive counselling where relevant.
- Topicals: First‑line for mild disease and useful in combination for moderate acne.
Patient selection criteria checklist: severity of acne, prior therapy failure, pregnancy risk, comorbidities and patient preference.
Common questions
- How long until I see improvement? Many patients see a reduction in inflammatory lesions within 4–8 weeks, with full benefit often by the end of the course.
- Will it affect my mood or sexual function? Some patients report mood changes; evidence is mixed. Screen at baseline and during treatment and seek urgent review for suicidal ideation.
- Can I donate blood? UK guidance advises no blood donation during treatment and for at least one month after cessation; check NHS Blood & Transplant for the latest guidance.
- What contraception is required? Typically two reliable forms of contraception starting before treatment and continuing after stopping as per prescriber protocol.
- Cheilitis
- Dry, inflamed lips commonly treated with emollient lip balms.
- Hypertriglyceridaemia
- Elevated blood triglycerides requiring lipid monitoring and possible dose adjustment.
Signpost: consult MHRA and NHS patient information for the latest safety guidance and reporting routes.
Registration and regulation
MHRA approval process
Isotretinoin products are MHRA‑regulated as Prescription‑Only Medicines and branded and generic versions undergo safety assessments.
MHRA requirements include a pregnancy prevention programme for the safety of patients.
Manufacturer leaflets, SmPCs and patient information leaflets contain mandated warnings and monitoring advice.
NHS prescribing framework
NHS prescribers must document baseline checks, informed consent and monitoring when prescribing isotretinoin.
Private dermatology clinics commonly adopt similar or more stringent safety protocols and must keep clear records.
Adverse drug reactions should be reported via the MHRA Yellow Card scheme and pharmacists are key gatekeepers at dispensing.
- Regulatory checklist for prescribers: confirm pregnancy status, document contraception advice, baseline blood tests, consent and monitoring schedule.
- Reporting routes: MHRA Yellow Card online or via the NHS reporting system.
| Approval step | Post‑marketing requirement |
|---|---|
| Product safety assessment | Ongoing pharmacovigilance and pregnancy prevention monitoring |
| SmPC and PIL publication | Update with safety signals and regulatory changes |
Storage and handling
UK household storage (cold/damp climate)
Store isotretinoin below 25°C in the original blister packaging and protect it from moisture and light.
Avoid storing capsules in bathrooms or near radiators and do not leave them in cars where temperatures vary.
Keep all medicines out of reach of children and pets and ensure capsules remain intact in their blister strips.
Guidance from NHS and pharmacists
Pharmacists should advise safe disposal of unused capsules and, because of teratogenic risk, follow local hazardous waste guidance when possible.
Transport in original packaging and return unused stock to the pharmacy for safe disposal if required.
- Storage do’s: keep in original blister; store at room temperature below 25°C; keep dry and out of light.
- Storage don’ts: do not store in bathroom or vehicle; do not transfer to unlabelled containers.
| Storage temperature | Action |
|---|---|
| Below 25°C | Store in original packaging. |
| Above 25°C | Avoid exposure; return to pharmacy if heat exposure occurred. |
Guidelines for proper use (practical counselling)
UK pharmacist counselling style
Cover dosing schedule and instruction to take with a meal to improve absorption.
Explain likely side effects such as cheilitis and dry skin and provide simple mitigation measures including emollients.
Discuss contraception and the need for pregnancy testing where relevant and document that counselling has taken place.
Explain required blood tests including LFTs and fasting lipids and the need to avoid alcohol and vitamin A supplements.
Advise when to seek help for severe mood change, vision changes or severe gastrointestinal symptoms.
NHS patient safety advice
Provide written information, document counselling and supply emergency contact details.
Remind patients not to donate blood while on isotretinoin and for the recommended period after stopping.
Ask patients to inform all other healthcare providers including dentists and ophthalmologists that they are taking isotretinoin.
Arrange follow‑up and ensure clear routes for reporting side effects via MHRA Yellow Card.
- Counselling checklist: take with food; expect dryness; contraception and pregnancy testing; blood test schedule; avoid alcohol and vitamin A supplements.
- Red flags prompting urgent review: suicidal ideation, severe visual disturbance, sudden severe abdominal pain, jaundice or marked muscle weakness.
Patient handout summary: take with food; use moisturiser and lip balm; attend blood tests at prescribed intervals; stop if pregnant or trying to conceive; contact pharmacy or GP for concerns.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | Greater London | 9–21 days |
| Birmingham | West Midlands | 9–21 days |
| Manchester | North West England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | West Yorkshire | 9–21 days |
| Sheffield | South Yorkshire | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Bristol | South West England | 9–21 days |
| Nottingham | East Midlands | 9–21 days |
| Newcastle Upon Tyne | North East England | 9–21 days |
| Southampton | South East England | 9–21 days |